{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:11:38Z","timestamp":1777993898164,"version":"3.51.4"},"reference-count":62,"publisher":"Mattioli1885","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: Present treatment methods for the management of androgenetic alopecia (AGA) have shortcomings. Though recent studies suggest that autologous micrograft technology (AMT) may be an effective alternative, smaller samples sizes in these studies calls for using statistical methods to get pooled effect sizes. Objectives: To compare the efficacy of AMT and finasteride in the management of AGA, using a meta-analysis study, comparators being hair count and percentage of patients benefitted from the treatment. Methods: A systematic review and meta-analysis was performed, using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. The protocol was registered in PROSPERO (Reg. No: CRD42024578804). Databases searched for potential articles includes: PubMed, ScienceDirect, CINAHL, Cochrane, MEDLINE-OVID, Embase-OVID, Web of Science Core Collection, and Bielefeld Academic Search Engine. Results:\u00a0This study suggest that AMT treatment may be superior to \u22651mg\/day finasteride for the management of AGA. With regards to improvement in hair count, both AMT (Hedges\u2019s g = 0.324, 95% CI: 0.198 \u2013 0.450; p&lt;0.001) and finasteride (Hedges\u2019s g = 0.251, 95% CI: 0.153 \u2013 0.349; p&lt;0.001) showed small effect sizes. When the percentage of patients benefitted is considered, AMT had a medium effect size (Hedges\u2019s g = 0.634, 95% CI: 0.372 \u2013 0.896; Z-value = 4.736; p&lt;0.001) whereas finasteride had a small effect size (Hedges\u2019s g = 0.201, 95% CI: 0.153 \u2013 0.248; p&lt;0.001). Conclusion: This study suggests that AMT is an effective method for promoting hair growth in patients with AGA and presents evidence for the superiority of AMT over finasteride.<\/jats:p>","DOI":"10.5826\/dpc.1602a6211","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:47:45Z","timestamp":1777571265000},"page":"6211","source":"Crossref","is-referenced-by-count":0,"title":["Autologous Micrograft Technology (AMT) and Finasteride for the Management of Androgenic Alopecia \u2013 A Systematic Review and Meta-analysis of the Efficacy and Safety"],"prefix":"10.5826","volume":"16","author":[{"given":"Adam","family":"Ellerby","sequence":"first","affiliation":[{"name":"Mercato Medical Byron Bay, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Knudsen","sequence":"first","affiliation":[{"name":"The Knudsen Clinic, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"10.5826\/dpc.1602a6211_ref1","doi-asserted-by":"crossref","unstructured":"Ntshingila S, Oputu O, Arowolo AT, Khumalo NP. Androgenetic alopecia: An update. JAAD Int. 2023;13:150-158. DOI:10.1016\/j.jdin.2023.07.005","DOI":"10.1016\/j.jdin.2023.07.005"},{"key":"10.5826\/dpc.1602a6211_ref2","unstructured":"Ho CH, Sood T, Zito PM. Androgenetic Alopecia. [Updated 2024 Jan 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430924\/"},{"key":"10.5826\/dpc.1602a6211_ref3","unstructured":"Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15-24. PMID: 24566563"},{"key":"10.5826\/dpc.1602a6211_ref4","doi-asserted-by":"crossref","unstructured":"Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023;83(8):701-715. DOI:10.1007\/s40265-023-01880-x","DOI":"10.1007\/s40265-023-01880-x"},{"key":"10.5826\/dpc.1602a6211_ref5","doi-asserted-by":"crossref","unstructured":"Martinez-Jacobo L, Villarreal-Villarreal CD, Ortiz-L\u00f3pez R, Ocampo-Candiani J, Rojas-Mart\u00ednez A. Genetic and molecular aspects of androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2018;84(3):263-268. DOI:10.4103\/ijdvl.IJDVL_262_17","DOI":"10.4103\/ijdvl.IJDVL_262_17"},{"key":"10.5826\/dpc.1602a6211_ref6","doi-asserted-by":"crossref","unstructured":"Sadasivam IP, Sambandam R, Kaliyaperumal D, Dileep JE. Androgenetic Alopecia in Men: An Update On Genetics. Indian J Dermatol. 2024;69(3):282. DOI:10.4103\/ijd.ijd_729_23","DOI":"10.4103\/ijd.ijd_729_23"},{"key":"10.5826\/dpc.1602a6211_ref7","doi-asserted-by":"crossref","unstructured":"Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9-17. DOI:10.1007\/s12020-017-1280-y","DOI":"10.1007\/s12020-017-1280-y"},{"key":"10.5826\/dpc.1602a6211_ref8","doi-asserted-by":"crossref","unstructured":"York K, Meah N, Bhoyrul B, Sinclair R. A review of the treatment of male pattern hair loss. Expert Opin Pharmacother. 2020;21(5):603-612. DOI:10.1080\/14656566.2020.1721463","DOI":"10.1080\/14656566.2020.1721463"},{"key":"10.5826\/dpc.1602a6211_ref9","doi-asserted-by":"crossref","unstructured":"Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759-3781. DOI:10.1111\/jocd.14537","DOI":"10.1111\/jocd.14537"},{"key":"10.5826\/dpc.1602a6211_ref10","doi-asserted-by":"crossref","unstructured":"Saceda-Corralo D, Dom\u00ednguez-Santas M, Va\u00f1\u00f3-Galv\u00e1n S, Grimalt R. What's New in Therapy for Male Androgenetic Alopecia? Am J Clin Dermatol. 2023;24(1):15-24. DOI:10.1007\/s40257-022-00730-y","DOI":"10.1007\/s40257-022-00730-y"},{"key":"10.5826\/dpc.1602a6211_ref11","doi-asserted-by":"crossref","unstructured":"Gupta AK, Mays RR, Dotzert MS, Versteeg SG, Shear NH, Piguet V. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(12):2112-2125. DOI:10.1111\/jdv.15081","DOI":"10.1111\/jdv.15081"},{"key":"10.5826\/dpc.1602a6211_ref12","doi-asserted-by":"crossref","unstructured":"Kerure AS, Patwardhan N. Complications in Hair Transplantation. J Cutan Aesthet Surg. 2018;11(4):182-189. DOI:10.4103\/JCAS.JCAS_125_18","DOI":"10.4103\/JCAS.JCAS_125_18"},{"key":"10.5826\/dpc.1602a6211_ref13","doi-asserted-by":"crossref","unstructured":"Garg AK, Garg S. Complications of Hair Transplant Procedures-Causes and Management. Indian J Plast Surg. 2021;54(4):477-482. DOI:10.1055\/s-0041-1739255.","DOI":"10.1055\/s-0041-1739255"},{"key":"10.5826\/dpc.1602a6211_ref14","doi-asserted-by":"crossref","unstructured":"Sharma R, Ranjan A. Follicular Unit Extraction (FUE) Hair Transplant: Curves Ahead. J Maxillofac Oral Surg. 2019;18(4):509-517. DOI:10.1007\/s12663-019-01245-6.","DOI":"10.1007\/s12663-019-01245-6"},{"key":"10.5826\/dpc.1602a6211_ref15","doi-asserted-by":"crossref","unstructured":"Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768-776. DOI:10.1067\/mjd.2000.107953.","DOI":"10.1067\/mjd.2000.107953"},{"key":"10.5826\/dpc.1602a6211_ref16","doi-asserted-by":"crossref","unstructured":"Gentile P, Scioli MG, Bielli A, Orlandi A, Cervelli V. Stem cells from human hair follicles: first mechanical isolation for immediate autologous clinical use in androgenetic alopecia and hair loss. Stem Cell Investig. 2017;4:58. DOI:10.21037\/sci.2017.06.04.","DOI":"10.21037\/sci.2017.06.04"},{"key":"10.5826\/dpc.1602a6211_ref17","doi-asserted-by":"crossref","unstructured":"Ruiz RG, Rosell JMC, Ceccarelli G, et al. Progenitor-cell-enriched micrografts as a novel option for the management of androgenetic alopecia. J Cell Physiol. 2020;235(5):4587-4593. DOI:10.1002\/jcp.29335","DOI":"10.1002\/jcp.29335"},{"key":"10.5826\/dpc.1602a6211_ref18","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI:10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.5826\/dpc.1602a6211_ref19","unstructured":"Study quality assessment tools. National Heart, Lung and Blood Institute, NIH. Accessed April 25, 2026. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"10.5826\/dpc.1602a6211_ref20","doi-asserted-by":"crossref","unstructured":"Brydges CR. Effect Size Guidelines, Sample Size Calculations, and Statistical Power in Gerontology. Innov Aging. 2019;3(4):igz036. DOI:10.1093\/geroni\/igz036.","DOI":"10.1093\/geroni\/igz036"},{"key":"10.5826\/dpc.1602a6211_ref21","doi-asserted-by":"crossref","unstructured":"Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863. DOI:10.3389\/fpsyg.2013.00863.","DOI":"10.3389\/fpsyg.2013.00863"},{"key":"10.5826\/dpc.1602a6211_ref22","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. DOI:10.1136\/bmj.327.7414.557.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"10.5826\/dpc.1602a6211_ref23","doi-asserted-by":"crossref","unstructured":"Borenstein M. Avoiding common mistakes in meta-analysis: Understanding the distinct roles of Q, I-squared, tau-squared, and the prediction interval in reporting heterogeneity. Res Synth Methods. 2024;15(2):354-368. DOI:10.1002\/jrsm.1678.","DOI":"10.1002\/jrsm.1678"},{"key":"10.5826\/dpc.1602a6211_ref24","doi-asserted-by":"crossref","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193-206. DOI:10.1037\/1082-989X.11.2.193.","DOI":"10.1037\/1082-989X.11.2.193"},{"key":"10.5826\/dpc.1602a6211_ref25","doi-asserted-by":"crossref","unstructured":"Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555-563. PMID: 10495375","DOI":"10.1016\/S0190-9622(99)70296-3"},{"key":"10.5826\/dpc.1602a6211_ref26","doi-asserted-by":"crossref","unstructured":"Gentile P, Scioli MG, Cervelli V, Orlandi A, Garcovich S. Autologous Micrografts from Scalp Tissue: Trichoscopic and Long-Term Clinical Evaluation in Male and Female Androgenetic Alopecia. Biomed Res Int. 2020;2020:7397162. DOI:10.1155\/2020\/7397162.","DOI":"10.1155\/2020\/7397162"},{"key":"10.5826\/dpc.1602a6211_ref27","unstructured":"\u00c1lvarez X, Valenzuela M, Tuffet J. Clinical and histological evaluation of the regenera\u00ae method for the treatment of androgenetic alopecia. IEASRJ. 2018;3(1). Accessed April 25, 2026. https:\/\/ieasrj.com\/journals\/index.php\/ieasrj\/article\/view\/89"},{"key":"10.5826\/dpc.1602a6211_ref28","unstructured":"\u00c1lvarez X, Valenzuela M, Tuffet J. Microscopic and Histologic Evaluation of the Regenera\u00ae Method for the Treatment of Androgenetic Alopecia in a Small Number of Cases. International Journal of Research Studies in Medical and Health Sciences. 2017;2:19\u201322."},{"key":"10.5826\/dpc.1602a6211_ref29","doi-asserted-by":"crossref","unstructured":"Chunmei W, Xian H, Yang B, Alkouz Z. Clinical trial efficacy of autologous cellular micrografts in androgenic alopecia. Research Square. 2023;2-17. DOI:10.21203\/rs.3.rs-2613149\/v1","DOI":"10.21203\/rs.3.rs-2613149\/v1"},{"key":"10.5826\/dpc.1602a6211_ref30","doi-asserted-by":"crossref","unstructured":"Gentile P. Autologous Cellular Method Using Micrografts of Human Adipose Tissue Derived Follicle Stem Cells in Androgenic Alopecia. Int J Mol Sci. 2019;20(14):3446. DOI:10.3390\/ijms20143446","DOI":"10.3390\/ijms20143446"},{"key":"10.5826\/dpc.1602a6211_ref31","doi-asserted-by":"crossref","unstructured":"Gentile P. Hair Regrowth with Micrografts Enriched with Human Follicle Mesenchymal Stem Cells and Platelet-Rich Plasma. In: Kalaaji, A. (eds) Plastic and Aesthetic Regenerative Surgery and Fat Grafting. Springer, Cham. 2022;595-602. DOI:10.1007\/978-3-030-77455-4_43","DOI":"10.1007\/978-3-030-77455-4_43"},{"key":"10.5826\/dpc.1602a6211_ref32","doi-asserted-by":"crossref","unstructured":"Krefft-Trzciniecka K, Ciso\u0144 H, Pakiet A, Nowicka D, Szepietowski JC. Enhancing Quality of Life and Sexual Functioning in Female Androgenetic Alopecia: Therapeutic Potential of Hair Follicle-Derived Stem Cells. Healthcare (Basel, Switzerland). 2024;12(6): 608. DOI:10.3390\/healthcare12060608","DOI":"10.3390\/healthcare12060608"},{"key":"10.5826\/dpc.1602a6211_ref33","doi-asserted-by":"crossref","unstructured":"Krefft-Trzciniecka K, Pi\u0119towska Z, Pakiet A, Nowicka D, Szepietowski JC. Short-Term Clinical Assessment of Treating Female Androgenetic Alopecia with Autologous Stem Cells Derived from Human Hair Follicles. Biomedicines. 2024;12(1): 153. DOI:10.3390\/biomedicines12010153","DOI":"10.3390\/biomedicines12010153"},{"key":"10.5826\/dpc.1602a6211_ref34","doi-asserted-by":"crossref","unstructured":"Zari S. Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A Retrospective Cohort Study. Clin Cosmet Investig Dermatol. 2021;14:1725\u20131736. DOI:10.2147\/CCID.S334807","DOI":"10.2147\/CCID.S334807"},{"key":"10.5826\/dpc.1602a6211_ref35","doi-asserted-by":"crossref","unstructured":"Harcha GW, Mart\u00ednez BJ, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489\u2013498.e3. DOI:10.1016\/j.jaad.2013.10.049","DOI":"10.1016\/j.jaad.2013.10.049"},{"key":"10.5826\/dpc.1602a6211_ref36","doi-asserted-by":"crossref","unstructured":"Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47\u201351. DOI:10.4103\/0378-6323.45220","DOI":"10.4103\/0378-6323.45220"},{"key":"10.5826\/dpc.1602a6211_ref37","doi-asserted-by":"crossref","unstructured":"Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998; 39(4 Pt 1):578\u2013589. DOI:10.1016\/s0190-9622(98)70007-6","DOI":"10.1016\/S0190-9622(98)70007-6"},{"key":"10.5826\/dpc.1602a6211_ref38","doi-asserted-by":"crossref","unstructured":"Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J. Investig. Dermatol. 1999;4(3):282\u2013284. DOI:10.1038\/sj.jidsp.5640230","DOI":"10.1038\/sj.jidsp.5640230"},{"key":"10.5826\/dpc.1602a6211_ref39","doi-asserted-by":"crossref","unstructured":"Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47\u201354. DOI:10.4103\/0378-6323.188652","DOI":"10.4103\/0378-6323.188652"},{"key":"10.5826\/dpc.1602a6211_ref40","doi-asserted-by":"crossref","unstructured":"Hu R, Xu F, Sheng Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. 2015;28(5):303\u2013308. DOI:10.1111\/dth.12246","DOI":"10.1111\/dth.12246"},{"key":"10.5826\/dpc.1602a6211_ref41","doi-asserted-by":"crossref","unstructured":"Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40(6 Pt 1):930\u2013937. DOI:10.1016\/s0190-9622(99)70081-2","DOI":"10.1016\/S0190-9622(99)70081-2"},{"key":"10.5826\/dpc.1602a6211_ref42","doi-asserted-by":"crossref","unstructured":"Yanagisawa M, Fujimaki H, Takeda A, Nemoto M, Sugimoto T, Sato A. Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia. Clinical Research and Trials. 2019;5:1-5. DOI: 10.15761\/CRT.1000273","DOI":"10.15761\/CRT.1000273"},{"key":"10.5826\/dpc.1602a6211_ref43","unstructured":"Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003;13(2):150\u2013160. PMID: 12695131."},{"key":"10.5826\/dpc.1602a6211_ref44","doi-asserted-by":"crossref","unstructured":"Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80(6):521\u2013525. DOI:10.4103\/0378-6323.144162","DOI":"10.4103\/0378-6323.144162"},{"key":"10.5826\/dpc.1602a6211_ref45","doi-asserted-by":"crossref","unstructured":"Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39(1):27\u201332. DOI:10.1111\/j.1346-8138.2011.01378.x","DOI":"10.1111\/j.1346-8138.2011.01378.x"},{"key":"10.5826\/dpc.1602a6211_ref46","doi-asserted-by":"crossref","unstructured":"Won YY, Lew BL, Sim WY. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg\/day in women with female pattern hair loss. Dermatol Ther. 2018;31(2):e12588. DOI:10.1111\/dth.12588","DOI":"10.1111\/dth.12588"},{"key":"10.5826\/dpc.1602a6211_ref47","doi-asserted-by":"crossref","unstructured":"Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46(4):517\u2013523. DOI:10.1067\/mjd.2002.120537","DOI":"10.1067\/mjd.2002.120537"},{"key":"10.5826\/dpc.1602a6211_ref48","doi-asserted-by":"crossref","unstructured":"Rossi A, Mari E, Scarno M, et al. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167\u20131173. DOI:10.1177\/039463201202500435","DOI":"10.1177\/039463201202500435"},{"key":"10.5826\/dpc.1602a6211_ref49","doi-asserted-by":"crossref","unstructured":"Rossi A, Cantisani C, Scarn\u00f2 M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455\u2013461. DOI:10.1111\/j.1529-8019.2011.01441.x","DOI":"10.1111\/j.1529-8019.2011.01441.x"},{"key":"10.5826\/dpc.1602a6211_ref50","doi-asserted-by":"crossref","unstructured":"Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804\u2013810. DOI:10.1046\/j.1365-2133.2000.03780.x","DOI":"10.1046\/j.1365-2133.2000.03780.x"},{"key":"10.5826\/dpc.1602a6211_ref51","doi-asserted-by":"crossref","unstructured":"Yoshitake T, Takeda A, Ohki K, et al. Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. J Dermatol. 2015;42(7):735\u2013738. DOI:10.1111\/1346-8138.12890","DOI":"10.1111\/1346-8138.12890"},{"key":"10.5826\/dpc.1602a6211_ref52","doi-asserted-by":"crossref","unstructured":"Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol. 2006;55(1):71\u201374. DOI:10.1016\/j.jaad.2005.07.001","DOI":"10.1016\/j.jaad.2005.07.001"},{"key":"10.5826\/dpc.1602a6211_ref53","unstructured":"Kishor A, Kumar J, Shrivastava MR, Zaman ZA. A Comparative Study of the Efficacy and Safety of 5% Minoxidil and 1 Mg Finasteride in Male Androgenetic Alopecia Patients at a Tertiary Centre in Bihar. Int J Pharm Clin Res. 2023;15(5):1982-1988."},{"key":"10.5826\/dpc.1602a6211_ref54","unstructured":"Bharti M, Singh S, Anshumali PA, et al. Comparative Evaluation of Efficacy and Safety of 5% minoxidil and 1 mg finasteride in Male Patients of Androgenetic Alopecia. IJHCR. 2021;4(13):391\u2013394. https:\/\/ijhcr.com\/index.php\/ijhcr\/article\/view\/2178"},{"key":"10.5826\/dpc.1602a6211_ref55","doi-asserted-by":"crossref","unstructured":"Shin JW, Chung EH, Kim MB, et al. Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. J Dermatol. 2019;46(2):139\u2013143. DOI:10.1111\/1346-8138.14719","DOI":"10.1111\/1346-8138.14719"},{"key":"10.5826\/dpc.1602a6211_ref56","doi-asserted-by":"crossref","unstructured":"Choi GS, Sim WY, Kang H, et al. Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study. Ann Dermatol. 2022;34(5):349\u2013359. DOI:10.5021\/ad.22.027","DOI":"10.5021\/ad.22.027"},{"key":"10.5826\/dpc.1602a6211_ref57","doi-asserted-by":"crossref","unstructured":"Arca E, A\u00e7ikg\u00f6z G, Ta\u015ftan HB, K\u00f6se O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology (Basel). 2004;209(2):117\u2013125. DOI:10.1159\/000079595","DOI":"10.1159\/000079595"},{"key":"10.5826\/dpc.1602a6211_ref58","unstructured":"Garg P. A comparative study of efficacy of 5% Minoxidil and 1 mg Finasteride in androgenetic alopecia male patients. Eur J Mol Clin Med. 2022;9(6):13-17. https:\/\/ejmcm.com\/issue-content\/a-comparative-study-of-efficacy-of-5-minoxidil-and-1-mg-finasteride-in-androgenetic-alopecia-male-patients-9119."},{"key":"10.5826\/dpc.1602a6211_ref59","doi-asserted-by":"crossref","unstructured":"Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5. DOI:10.1016\/j.jaad.2017.02.054.","DOI":"10.1016\/j.jaad.2017.02.054"},{"key":"10.5826\/dpc.1602a6211_ref60","doi-asserted-by":"crossref","unstructured":"Aukerman EL, Jafferany M. The psychological consequences of androgenetic alopecia: A systematic review. J Cosmet Dermatol. 2023;22(1):89-95. DOI:10.1111\/jocd.14983.","DOI":"10.1111\/jocd.14983"},{"key":"10.5826\/dpc.1602a6211_ref61","doi-asserted-by":"crossref","unstructured":"Tas B, Kulacaoglu F, Belli H, Altuntas M. The tendency towards the development of psychosexual disorders in androgenetic alopecia according to the different stages of hair loss: a cross-sectional study. Ann Bras Dermatol. 2018;93(2):185-190. DOI:10.1590\/abd1806-4841.20185658.","DOI":"10.1590\/abd1806-4841.20185658"},{"key":"10.5826\/dpc.1602a6211_ref62","doi-asserted-by":"crossref","unstructured":"Fabbrocini G, Cantelli M, Masar\u00e0 A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4(4):203-211. DOI:10.1016\/j.ijwd.2018.05.001.","DOI":"10.1016\/j.ijwd.2018.05.001"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/6211\/3854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/6211\/3853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:23:51Z","timestamp":1777991031000},"score":1,"resource":{"primary":{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/view\/6211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1602a6211","relation":{"has-manifestation":[{"id-type":"other","id":"1-83-6211-g3853","asserted-by":"subject"},{"id-type":"other","id":"1-83-6211-g3854","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1602a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"7"}}